Canada Markets closed

Imagine Owning Aequus Pharmaceuticals (CVE:AQS) While The Price Tanked 56%

Simply Wall St

Investing in stocks inevitably means buying into some companies that perform poorly. But the long term shareholders of Aequus Pharmaceuticals Inc. (CVE:AQS) have had an unfortunate run in the last three years. So they might be feeling emotional about the 56% share price collapse, in that time. And more recent buyers are having a tough time too, with a drop of 22% in the last year. Shareholders have had an even rougher run lately, with the share price down 22% in the last 90 days.

See our latest analysis for Aequus Pharmaceuticals

Aequus Pharmaceuticals isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally expect to see good revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

In the last three years, Aequus Pharmaceuticals saw its revenue grow by 36% per year, compound. That's well above most other pre-profit companies. The share price has moved in quite the opposite direction, down 24% over that time, a bad result. It seems likely that the market is worried about the continual losses. When we see revenue growth, paired with a falling share price, we can't help wonder if there is an opportunity for those who are willing to dig deeper.

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

TSXV:AQS Income Statement, October 25th 2019

Balance sheet strength is crucial. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.

A Different Perspective

The last twelve months weren't great for Aequus Pharmaceuticals shares, which cost holders 22%, while the market was up about 8.3%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. However, the loss over the last year isn't as bad as the 24% per annum loss investors have suffered over the last three years. We would want clear information suggesting the company will grow, before taking the view that the share price will stabilize. Before spending more time on Aequus Pharmaceuticals it might be wise to click here to see if insiders have been buying or selling shares.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on CA exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.